**1. Introduction**

Hematological malignancies contain an accumulation of heterogeneous conditions, by which is commonly affect old ages, as the median age for most of these diseases all originating from cells of the bone marrow and the lymphatic system. There are three noteworthy gatherings: lymphomas, leukemia and plasma cell neoplasms. European patients with hematological malignancies have improved over the previous decade, most likely as a result of new medications, for example, imatinib in chronic myeloid leukemia and rituximab in lymphomas [1].

In developed countries and developing countries hematological malignancies (HMs) are differs and account about 8–9% of all cancers, being the fourth common cancer in developed countries [2]. The leukemia incidence rates are 24.5 per 100,000 is 8.8% in the US, 6.3% in Jordan, 5.4% in Egypt [3] The lymphoma incidence rate have been reported to be high in Canada (27.7%), Australia (25%) and Western Europe (17.9%), moderate (10.2%) in Middle East and Africa and low (6.5%) in East Asia [3].

While the previous 20 years witnessed an explosion in the quantity approved treatments for lymphoid and myeloid malignancies and few medications were endorsed, especially for leukemia, lymphoma and myeloma. This was astounding in light of comparable, if not more prominent, propels in the comprehension of the genetic basis and pathophysiology of hematological malignancies, which account 8–24% of every single grown-up disease [1]. The test of making an interpretation of these logical revelations into powerful treatments for patients with hematological malignancies established as an urgent unmet medical need.
